Business Description
Compare
Compare
Traded in other countries / regions
0VY.GermanyIMAB.USA IPO Date
2020-01-17Description
I-Mab Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will be felzartamab for the China market, a CD38 inhibitor for multiple myeloma, which we estimate will be launched in late 2023 or early 2024. Core assets include lemzoparlimab, a potential best-in-class CD47 inhibitor; uliledlimab, a potential best-in-class CD73 inhibitor; and eftansomatropin, a long-acting growth hormone that has a large market in China among pediatric patients with short stature.
Financial Strength
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 37.77 | |||||
Equity-to-Asset | 0.81 | |||||
Debt-to-Equity | 0.03 | |||||
Debt-to-EBITDA | -0.05 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 1/9 | |||||
Altman Z-Score | -0.61 | |||||
Beneish M-Score | 2.25 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 1.3 | |||||
3-Year EBITDA Growth Rate | -56.1 | |||||
3-Year EPS without NRI Growth Rate | -32.8 | |||||
3-Year FCF Growth Rate | -29.1 |
Momentum Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 14.24 | |||||
9-Day RSI | 21.16 | |||||
14-Day RSI | 27.12 | |||||
6-1 Month Momentum % | -8.24 | |||||
12-1 Month Momentum % | -76.22 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 7.31 | |||||
Quick Ratio | 7.31 | |||||
Cash Ratio | 6.65 | |||||
Days Inventory | 137.41 | |||||
Days Sales Outstanding | 51.22 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -21.5 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 39.5 | |||||
Operating Margin % | -1511.75 | |||||
Net Margin % | -1882.23 | |||||
ROE % | -48.96 | |||||
ROA % | -41.06 | |||||
ROIC % | -218.68 | |||||
ROC (Joel Greenblatt) % | -1653.18 | |||||
ROCE % | -42.42 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 13.45 | |||||
PB Ratio | 0.43 | |||||
Price-to-Tangible-Book | 0.47 | |||||
EV-to-EBIT | 0.92 | |||||
EV-to-Forward-EBIT | -0.01 | |||||
EV-to-EBITDA | 0.94 | |||||
EV-to-Forward-EBITDA | -0.01 | |||||
EV-to-Revenue | -15.97 | |||||
EV-to-Forward-Revenue | 0.23 | |||||
EV-to-FCF | 1.72 | |||||
Price-to-Net-Current-Asset-Value | 0.52 | |||||
Price-to-Net-Cash | 0.59 | |||||
Earnings Yield (Greenblatt) % | 108.7 |
How I-MAB (IMAB) Makes Its Money
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:IMAB
Peter Lynch Chart
Performance
Dividend
Log
Annualized Return %
Total Annual Return %
I-MAB Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 18.776 | ||
EPS (TTM) ($) | -4.42 | ||
Beta | 1.09 | ||
Volatility % | 94.96 | ||
14-Day RSI | 27.12 | ||
14-Day ATR ($) | 0.323249 | ||
20-Day SMA ($) | 3.779 | ||
12-1 Month Momentum % | -76.22 | ||
52-Week Range ($) | 2.73 - 21.44 | ||
Shares Outstanding (Mil) | 83.1 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 1 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
I-MAB Filings
Document | Form | Filing Date | ||
---|---|---|---|---|
No Filing Data |
I-MAB Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
I-MAB Frequently Asked Questions
What is I-MAB(IMAB)'s stock price today?
The current price of IMAB is $3.14. The 52 week high of IMAB is $21.44 and 52 week low is $2.73.
When is next earnings date of I-MAB(IMAB)?
The next earnings date of I-MAB(IMAB) is 2023-03-29 Est..
Does I-MAB(IMAB) pay dividends? If so, how much?
I-MAB(IMAB) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |